ERBB2 and breast carcinoma: In breast carcinomas it has been shown that HER2/NEU amplification/overexpression has therapeutic and prognostic implications (Slamon 1990; Meric et al, 2002; Hudelist et al, 2003; Witton et al, 2003; Abd El-Rehim et al, 2004; Bianchi et al, 2006), and that the monoclonal antibody trastuzumab directed against HER2/NEU is therapeutically active in HER2-positive breast carcinomas (Meric et al, 2002; Menard et al, 2003).